Therapeutic opportunities to control tumor cell cycles
- 114 Downloads
Tumor cell proliferation is frequently associated to genetic or epigenetic alterations in key cell cycle regulators. Most human tumors deregulate this pathway to sustain proliferation with independence of external mitogenic factors. In addition, the alteration of cell cycle proteins may confer genomic instability that results in additional mutations in these tumor cells. The frequent alteration of the cell cycle in tumor cells has launched the identification for critical cell cycle regulators as anticancer targets. The inhibition of some cell cycle kinases such as cyclin-dependent kinases (CDKs) or the Aurora and Polo mitotic kinases is currently under study in several preclinical and clinical trials. Similarly, the clinical success of microtubule poisons such as taxol has promoted new applied research in mitosis regulation. Recent investigations have suggested new targets of interest including additional kinases, phosphatases and other mitotic regulators such as microtubule motor proteins (kinesins). Current research in this area will undoubtedly result in new and improved targeted therapies for cancer treatment.
Key wordscyclin-dependent kinases Aurora Polo phosphatases kinesins cell cycle genomic instability cancer therapy
Unable to display preview. Download preview PDF.
- 5.Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Progress Cell Cycle Res. 2003;5:5–18.Google Scholar
- 6.Ortega S, Malumbres M, Barbacid M. Cdk4 and their INK4 inhibitors in tumor biology. Biochem Biophys Acta. 2002;87513:1–15.Google Scholar
- 13.Blagosklonny MV. Flavopiridol, an inhibitor of transcription. Implications, problems and solutions. Cell Cycle. 2004;3: 1557–42.Google Scholar
- 22.Tao W. The mitotic checkpoint in cancer therapy. Cell Cycle. 2005;4:e103-e7.Google Scholar
- 38.Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2005; [doi:10.1016/j.canlet. 2005. 06.017].Google Scholar
- 57.Skoufias DA, Debonis S, Saoudi Y, et al. S-trityl-l-cysteine is a reversible, tight-binding inhibitor of the human kinesin eg5 that specifically blocks mitotic progression. J Biol Chem. 2006 [J. Biol. Chem, 10.1074/jbc.M511735200].Google Scholar